Products

Article

Products

Surgery platform

The OS4 will be premiered at the Oertli booth, B09, during the congress exhibition. "We have redefined the concept of the operating platform for cataract, glaucoma and retina surgery," said Thomas Bosshard, head of marketing and sales. "The OS4 includes everything we are good at: cutting-edge technology, perfect design, irresistible simplicity, the highest degree of safety and Swiss quality."

More information can also be found at http://www.oertli-instruments.com/

DSAEK lamella preparation

According to the company, the new head provides flexibility and tool management simplicity. A combination of new technologies have been built into this new device and are compatible as an upgrade with existing Gebauer SLc systems.

If you would like further details visit the company booth at H18 or have a look at the website http://www.gebauermedical.com/

IOP monitoring

The device is based on a rebound measuring principle that does not require topical anaesthesia, air or specialized skills to use it. It is easy-to-use and provides quick, accurate and effective IOP measurements for patient comfort.

Visit the company at booth, B05, for further information. Alternatively, you can learn more at http://www.icaretonometer.com/

Mini-incision injector

This new injector has been approved for the safe and effective implantation of the C-flex Aspheric and Superflex Aspheric ranges of lenses through 2.2 mm wound assisted mini incision. It is supplied in a system pack format with the IOL, ensuring that the user always employs a certified injector with the specific lens.

"Much like the earlier 2.7 mm Rayner injectors and the later 2.4 mm RaySert injectors, the new 2.2 mm RaySert PLUS has a very easy and simple loading mechanism," confirmed Mr Allon Barsom (consultant ophthalmic surgeon specialist in cornea, cataract and laser eye surgery at Luton and Dunstable University Hospital, UCL Partners, UK). "The one handed injector frees up the non-dominant hand for counter fixation to facilitate a controlled and gentle wound assisted delivery of the lens into the capsular bag."

Further details can be found at the website http://www.rayner.com/

*Please note the incorrect booth numbers were highlighted last month, Rayner will be exhibiting at booths: E11 and J02

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.